Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

BACKGROUND: Patients with metastatic breast cancer are frequently treated with anthracyclines and taxanes, which are among the most active agents in this disease. Gemcitabine is an interesting candidate for a three-drug combination because of its different mechanism of action and non-overlapping tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Passardi, Alessandro, Massa, Ilaria, Zoli, Wainer, Gianni, Lorenzo, Milandri, Carlo, Zumaglini, Federica, Nanni, Oriana, Maltoni, Roberta, Frassineti, Giovanni Luca, Amadori, Dino
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434761/
https://www.ncbi.nlm.nih.gov/pubmed/16551351
http://dx.doi.org/10.1186/1471-2407-6-76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1434761/
https://www.ncbi.nlm.nih.gov/pubmed/16551351
http://dx.doi.org/10.1186/1471-2407-6-76

Ejemplares similares